The DOT1L inhibitor EPZ004777 downregulated ERα levels and markedly decreased tumor size after 3 weeks of treatment in hormone-positive and anti-estrogen-resistant breast cancer cells [229]. This evidence concerns the gene DOT1L and breast carcinoma.